Rapidly progressive glomerulonephritis future or investigational therapies
|
Rapidly progressive glomerulonephritis Microchapters |
|
Differentiating Rapidly progressive glomerulonephritis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Rapidly progressive glomerulonephritis future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Rapidly progressive glomerulonephritis future or investigational therapies |
|
FDA on Rapidly progressive glomerulonephritis future or investigational therapies |
|
CDC on Rapidly progressive glomerulonephritis future or investigational therapies |
|
Rapidly progressive glomerulonephritis future or investigational therapies in the news |
|
Blogs on Rapidly progressive glomerulonephritis future or investigational therapies |
|
Directions to Hospitals Treating Rapidly progressive glomerulonephritis |
Stem Cell Therapy:
Stem cell therapy is at an early phase of development, but it can be a good future therapeutic strategy in immune-mediated renal disease. There is some experimental evidence in animal models of anti-GBM disease, where mesenchymal stem cells were usedwheres, which are progenitors of renal tissue. ]. A case of NCGN due to MPA successfully treated with stem cell therapy has been reported. The patient's serum creatinine peaked at 690 µmol/L; standard therapy with cyclophosphamide and glucocorticoids was ineffective, and rituximab was not tolerated; following treatment with autologous mesenchymal stem cells, the patient's creatinine came down to 168 µmol/L in parallel with a reduction in the ANCA titre.[1]
References
- ↑ Huang ZY, Hong LQ, Na N, Luo Y, Miao B, Chen J (March 2012). "Infusion of mesenchymal stem cells overexpressing GDNF ameliorates renal function in nephrotoxic serum nephritis". Cell Biochem. Funct. 30 (2): 139–44. doi:10.1002/cbf.1827. PMID 22105543.